Dr. Lee Albacker, PhD, leads immunotherapy biomarker research at Foundation Medicine. His team has studied how the natural history of tumor-immune interactions affects checkpoint inhibitor response, leading to the discovery of STK11 as a negative predictor of response. Using big-data approaches, his team is beginning to understand the complex interplay of multiple checkpoint inhibitor biomarkers. Dr Albacker was classically trained in immunology as a graduate student at Harvard University and then went on to study cancer genomics as a post-doc in the Harvard Department of Systems Biology.